Trial Profile
Effects of Rituxan in patients with Polyneuropathies associated with serum IgM autoantibodies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- 22 Oct 2014 New trial record